Introduction {#Sec1}
============

Split-hand foot malformation (SHFM) also known as ectrodactyly is a congenital limb defect affecting predominantly the central rays of hands and/or feet. It may manifest either as an isolated trait or part of a multiple congenital anomaly syndrome. SHFM occurs with the incidence of about 1 per 18,000 liveborn infants and accounts for 8-17 % of all limb malformations (Czeizel et al. [@CR10]). SHFM is a clinically heterogeneous abnormality, which ranges from a relatively mild defect, such as hypoplasia of a single phalanx or syndactyly, to the aplasia of one or more central digits (i.e., classical cleft also known as lobster-claw anomaly, see Fig. [1a](#Fig1){ref-type="fig"}). In its most severe form - monodactyly - the defect is characterized by the aplasia of both central and preaxial rays of the autopod (Fig. [1b](#Fig1){ref-type="fig"}) (Jamsheer [@CR24]). As a consequence, interindividual and intrafamilial variability of the SHFM is very high. Furthermore, variable expressivity of this feature can be so significant, that a different pattern of anomaly is seen in each limb of the same individual patient (Temtamy and McKusick [@CR46]). The condition is mostly sporadic, familial forms are uncommon. In the majority of cases SHFM undergoes autosomal dominant mode of inheritance with reduced penetrance but other types of inheritance have also been reported (see Table [1](#Tab1){ref-type="table"}).Fig. 1Schematic presentation of the different anatomical types of SHFM (**a**) classical cleft characterized by the aplasia of the central rays of the autopod; (**b**) monodactyly characterized by the aplasia of both central and preaxial rays of the autopodTable 1Clinical and molecular characteristics of different SHFM lociSHFM locusType of mutationFrequency of mutationInheritance patternsLimb phenotypesSyndromes/non-limb phenotypesReferencesSHFM1rearrangements in 7q21.3-q22.1NDADSHFMEEC/Sensorineural deafness, MRCrackower et al. ([@CR8])*DLX5* mutationreported in 1 familyARShamseldin et al. ([@CR41])SHFM2Xq26reported in 1 familyXRSHFM, syndactyly, metacarpal hypoplasia, phalangeal hypoplasiaNAFaiyaz ul Haque et al. ([@CR19])SHFM3dup10q2420 %ADSHFM, triphalangeal and/or duplicated thumbs,NAde Mollerat et al. ([@CR11])SHFM4*TP63* mutation10-16 % (non-syndromic); 93 % (EEC syndrome)ADSHFMEEC, ADULT, LADD, CHARGE, VATER/MRvan Bokhoven et al. ([@CR48]); de Mollerat et al. ([@CR11])SHFM5del2q31NDADSHFMMR, ectodermal and craniofacial findings, orofacial cleftingGoodman et al. ([@CR20])SHFM6*WNT10B* mutationreported in 3 families, 1 sporadic caseARSHFM, tibial aplasia/hypoplasiaNAUgur and Tolun ([@CR47]); Blattner et al. ([@CR6]); Khan et al. ([@CR22])SHFM/SHFLDdup17p13.312 % (SHFM); 90 % (SHFLD)ADSHFM, tibial aplasia/hypoplasiaNAKlopocki et al. ([@CR27])SHFM -- split hand/foot malformation; SHFLD -- split hand/foot malformation with long bone deficiencydup10q24 -- duplication in locus 10q24; del2q31 -- deletion in locus 2q31; dup 17p13.3 -- duplication in locus 17p13.3AD -- autosomal dominant, AR -- autosomal recessive, XR -- X-linked recessiveEEC -- ectrodactyly-ectodermal dysplasia-cleft lip/palate, ADULT -- acro-dermato-ungual-lacrimal-tooth syndrome, LADD -- lacrimo-auriculo-dento-digital syndrome, CHARGE -- CHARGE syndrome (the letters stand for: coloboma of the eye, heart defects, atresia of the nasal choanae, retardation of growth and/or development, genital and/or urinary abnormalities, and ear abnormalities and deafness), VATER -- VATER association (the letters stand for: vertebral anomalies, anal atresia, cardiovascular anomalies, tracheoesophageal fistula, renal and/or radial anomalies, limb defects; MR -- mental retardationND -- no data; NA -- not applicable

In this review, we focus on the known molecular basis of isolated SHFM. We provide clinical and molecular information about each type of abnormality as well as discuss the underlying pathways and mechanism that contribute to their development (see Table [1](#Tab1){ref-type="table"}). Recent progress in the understanding of SHFM pathogenesis currently allows for identification of causative genetic changes in about 50 % of the patients affected by this condition. Therefore, we propose a diagnostic flow-chart helpful in the planning of molecular genetic tests aimed at identifying disease causing mutation. Finally, we address the issue of genetic counseling, which can be extremely difficult and challenging especially in sporadic SHFM cases.

Developmental aspects of SHFM formation {#Sec2}
---------------------------------------

The developing limb bud consists of two cell layers: highly proliferating mesenchymal cells covered by the ectodermal cells. The formation of limb bud is mediated by signaling molecules produced by three specialized cell groups - the apical ectodermal ridge (AER), the progress zone (PZ), and the zone of polarizing activity (ZPA). The interaction between these three regions determine the patterning of the limb in three spatial dimensions: proximo-distal, antero-posterior, and dorso-ventral. A number of signaling molecules and transcription factors such as fibroblast growth factors (FGFs), bone morphogenic proteins (BMPs) or WNT and MSX proteins produced by AER keep the neighboring mesenchymal cells in constant proliferation and undifferentiated state, giving rise to PZ (Gurrieri et al. [@CR21]). Constantly proliferating cells of PZ determine the proximo-distal polarity of the limb bud. Failure in maintaining the AER affects the formation of the autopod and leads to the development of SHFM phenotype. Not only genetic, but also environmental factors that include apoptosis in the AER can cause SHFM (Sulik and Dehart [@CR44]). Several genetic factors responsible for SHFM development have been identified to date.

Known SHFM loci {#Sec3}
---------------

### SHFM1 (7q21) {#Sec4}

Split hand/foot malformation type 1 (SHFM1) is caused by chromosomal rearrangements of the 7q21.3-q22.1 region (Fig. [2a](#Fig2){ref-type="fig"}). They occur mostly as *de novo* mutational events, but can also be inherited in an autosomal dominant manner, with reduced penetrance and variable expression. Genomic alteration of the SHFM1 locus can be either associated with isolated or syndromic limb malformation. For instance, sensorineural deafness is noted in 35 % of patients, while EEC symptoms (ectrodactyly-ectodermal dysplasia-cleft lip/palate) are much less frequent (Tackels-Horne et al. [@CR45]). Aberrations within this region involve translocations, inversions, duplications, and most frequently, deletions. The minimal overlapping region for SHFM1 encompass several genes involved in limb development, such as *DSS1*, *DLX5*, and *DLX6* (Crackower et al. [@CR8]; Duijf et al. [@CR15]). Crackower et al. ([@CR8]) found that the murine ortholog of *DSS1* is predominantly expressed in the mesenchyme of the developing limb bud, facial primordia, as well as in the branchial arches, genital tubercle, and dermis. It was proposed that the reduced expression of *DSS1* during the early stages of embryogenesis might be responsible for SHFM (Crackower et al. [@CR8]). However, the two other genes located within the 7q21-22 critical region, i.e., *DLX5* and *DLX6*, were found to be more attractive candidate genes for SHFM. Both belong to the members of the Wnt signaling pathway, which is important in limb skeleton development and morphogenesis (van Silfhout et al. [@CR49]). Expression of the murine orthologs - *Dlx5* and *Dlx6* - has been detected in the AER of the embryonic limb buds, in the pharyngeal arches, in the osteoblasts of developing bones, and in the inter neurons of the basal forebrain (Simeone et al. [@CR43]; Acampora et al. [@CR1]; Lo Iacono et al. [@CR32]). Both gene products are critical for the maintenance of the proliferation of medial AER cell population in the developing limb bud (Robledo et al. [@CR39]). The role of *DLX5*/*DLX6* in limb morphogenesis has been demonstrated in mouse models, where the double knock-out of both genes (*Dlx5*/*Dlx6*^−/−^) resulted in a typical ectrodactyly as well as craniofacial and inner ear abnormalities. Interestingly, the deletion of neither gene alone has led to ectrodactyly or other limb phenotype (Robledo et al. [@CR39]). Of note, the SHFM in *Dlx5*/*Dlx6*^−/−^ null mice could be rescued by solely overexpressing *Dlx5* in the AER suggesting *Dlx5* and *Dlx6* redundancy in limb development (Robledo et al. [@CR39]). On the other hand, overexpression of *Dlx5* in wild-type mice has no negative effect on limb formation. The hypothesized *DLX5* and/or *DLX6* biological activity is that they function as repressors of downstream target genes, which in the absence of both *DLX5* and *DLX6* are overexpressed, thereby giving rise to the reduction of cell proliferation within the AER (Robledo et al. [@CR39]).Fig. 2Limbs of the SHFM patients with different molecular origin of the defect (**a**) male proband with a classical cleft of the hands carrying a balanced chromosomal translocation t(7;12)(q21.2;q21.3) involving SHFM1 locus; (**b**, **c**) female proband carrying a typical 10q24 duplication of the SHFM3 locus showing ectrodactyly and preaxial polydactyly of the hands as well as ectrodactyly of the feet; (**d**) female proband with a classical cleft of the feet carrying a nonsense heterozygous point mutation c.G1974A(p.W658X) in the *TP63* gene

The mouse model for SHFM1 varies significantly from the clinical setting observed in human individuals. While mouse double *Dlx5*/*Dlx6*^−/−^ knock-out is recessive, human patients develop the condition if the aberration affects only a single copy of SHFM1 locus. Consequently, human SHFM1 deletions are inherited in an autosomal dominant manner. Thus, based on the interspecies differences, one can hypothesize that human limb development is more sensitive to reduced levels of DLX5/6 proteins (Robledo et al. [@CR39]). To make things more complex, haploinsufficiency of SHFM1 locus is not the only pathomechanism leading to limb defect in human individuals. Alternative mechanisms occur in the case of chromosomal translocations or inversions affecting SHFM1 locus and include \"position effect\" on *DLX5*/*DLX6* genes resulting either from the disruption of the regulatory elements or from changing the regulatory landscape on 7q21 (Merlo et al. [@CR34]). Transcriptional regulation of *DLX5* and *DLX6* genes has been investigated by several authors. Lo Iacono et al. ([@CR32]) have shown that DLX proteins and p63 transcription factor, encoded by *TP63* gene, colocalize in the AER and that p63 acts as an upstream regulator of *Dlx5* and *Dlx6* transcription via binding to their cis-acting regulatory elements at the promoter level. Heterozygous mutations in *TP63* give rise to limb malformations in multiple congenital syndromes as well as to isolated SHFM (SHFM4 - described below). Genome-wide profiling of *TP63* cis-regulatory elements and target genes, reported by Kouwenhoven et al. identified p63 binding site - SHFM1-BS1, that can function as an enhancer element controlling the expression of *DLX6*, and possibly *DLX5*, by physical interaction with *Dlx6* promoter (zebrafish and mice assay) (Kouwenhoven et al. [@CR29]). The expression of *Dlx5*/*Dlx6* is reduced upon p63 inactivation (Lo Iacono et al. [@CR32]) or disruption of regulatory elements controlled by p63 (Kouwenhoven et al. [@CR29]). Recent studies in the transcriptional regulation of *DLX5*/*6* resulted in the identification of additional enhancers located in protein coding sequences of the neighboring genes. Birnbaum et al. ([@CR5]) have described two novel limb exonic enhancers, (eExons) *DYNC1I1* eExon 15 and 17, that reside proximal to *DLX5*/*6*. With the use of mouse and zebrafish transgenic enhancer assays the authors characterized the enhancer activity of *DYNC1I1* eExon 15 in the AER and *DYNC1I1* eExon 17 in the anterior mesenchyme, and thus showed their regulatory influence on *Dlx5*/*6* limb expression (Birnbaum et al. [@CR5]). The above findings gave a new insight to putative genes, regulatory elements and novel disease mechanisms in the etiopathogenesis of SHFM1.

Recently, Shamseldin et al. ([@CR41]) studied a consanguineous family of putative autosomal recessive SHFM and found that homozygous *DLX5* missense mutation located in the homeodomain was causative for the limb phenotype. Thus, the authors provided the first strong evidence on direct *DLX5* involvement in the pathogenesis of human SHFM1 (Shamseldin et al. [@CR41]).

### SHFM2 (Xq26) {#Sec5}

To date only one family has been reported with X-lined inheritance of SHFM (Ahmad et al. [@CR2]). The authors described a consanguineous Pakistani family of which 36 individuals manifested full-blown SHFM (33 males and three females). The patients exhibited monodactylous or bidactylous hands and typical, but slightly variable feet. About half of the heterozygous females showed mild hand and/or foot malformations. Cytogenetic studies excluded the possibility of X/autosome translocations (Ahmad et al. [@CR2]). The X-linked inheritance of the trait in this family was later confirmed by linkage analysis which mapped the SHFM2 locus to Xq26 (Faiyaz ul Haque et al. [@CR19]). Two genes located in this region, *FGF13* and *TONDU*, may potentially be the candidate genes for SHFM2, however no coding mutations have been found in the above genes in patients with SHFM (Vaudin et al. [@CR50]).

### SHFM3 (10q24) {#Sec6}

The locus for SHFM3 maps to chromosome 10q24 and the causative rearrangement involves a submicroscopic tandem duplication spanning a region of 325--570 kb (de Mollerat et al. [@CR11]; Dimitrov et al. [@CR14]). Duplications of the SHFM3 locus are probably the most frequent cause of SHFM in humans and accounts for about 20 % of cases (Klopocki et al. [@CR27]). Several genes potentially contributing to the SHFM phenotype located within the duplicated region include *DACTYLIN* (*SFHM3*), *BTRC*, *POLL*, *FGF8*, and *LBX1*. The SHFM3 duplication is inherited in an autosomal dominant manner and associates mostly with the non-syndromic classical SHFM, which is frequently accompanied with preaxial abnormalities such as triphalangeal and/or duplicated thumbs (see Fig. [2b and c](#Fig2){ref-type="fig"}) (Everman et al. [@CR18]).

The naturally occurring *Dactylaplasia* (*Dac*) mouse is considered to be an animal model for human SHFM3. Both human and mouse SHFM3 regions (*Dac* locus maps to chromosome 19) share a high degree of homology. The *Dac* mice display the absence of central digits, hypoplasia or aplasia of metacarpal/metatarsal bones and syndactyly. The phenotype is inherited in a semi-dominant manner, i.e., heterozygotes present with the absence of central digits of hind- and forelimbs, whereas homozygotes show monodactyly (Johnson et al. [@CR26]; Sidow et al. [@CR42]). The mechanism that underlies the loss of digits in *Dac* mutants involves increased cell death in a specific portion of the AER. In *Dac*/+ (heterozygous) mice only the central part of AER is degenerated, whereas in *Dac*/*Dac* (homozygous) mice both the central and the anterior part of the AER are affected (Seto et al. [@CR40]; Crackower et al. [@CR9]).

The mechanism by which the duplication of the SHFM3 critical region gives rise to the limb defect remains unknown. Possible explanations are that either the aberrant *DACTYLIN* transcript exhibits a dominant negative effect on wild-type alleles or that the overexpression of other duplicated genes takes place, among which *BTRC* (β-*TRCP*) is of particular interest (de Mollerat et al. [@CR12]). *BTRC* functions as a ubiquitination factor of proteins involved in several signaling transduction pathways such as Wnt/β-catenin, SHH, and NF-κB (Maniatis [@CR33]). All these pathways are involved in limb development, therefore dysregulation of *BTRC* expression in a dosage dependent manner may be responsible for the SHFM3 phenotype (de Mollerat et al. [@CR11]). *FGF8* also located within the SHFM3 critical region induces and regulates the limb bud patterning via AER signaling. *Fgf8* mouse ortholog is highly expressed throughout the AER. Its inactivation in early limb ectoderm causes hypoplasia/aplasia of specific distal skeletal elements and alters the expression of *Shh* and *Bmp2* genes (Lewandoski et al. [@CR30]; Moon and Capecchi [@CR36]). To date, no pathogenic mutations have been reported in any of the putative candidate genes. Another mechanism that should be taken into consideration is a cis-acting position effect that gives rise to the skewed expression of genes flanking the breakpoints of the duplication (de Mollerat et al. [@CR12]).

### SHFM4 (3q27; *TP63*) {#Sec7}

A fourth SHFM locus was mapped to 3q27 region and is directly associated with mutations in *TP63* (also known as *P63*) gene (Ianakiev et al. [@CR23]). This is the only locus of monogenic etiology inherited in an autosomal dominant fashion. The protein encoded by *TP63* gene is a transcription factor homologous to tumor suppressor gene *TP53*. TP63 plays a crucial role in the embryonic development since it regulates the formation and differentiation of the AER. It functions as a key regulator of ectodermal development by maintaining the proliferative potential of ectodermal cells (Mills et al. [@CR35]; Yang et al. [@CR53]). TP63 controls the epithelial stratification process via regulation of AER-restricted genes (Koster et al. [@CR28]). Mice lacking *p63* fail to form normal ectodermal structures, which is manifested as developmental abnormalities of the skin, hair, teeth, craniofacial skeleton, mammary glands, and limbs, including ectrodactyly or other partial limb truncations or amelia (Mills et al. [@CR35]; Yang et al. [@CR53]). The lack of morphologically recognizable AER in the limb buds of *p63*-null mice results in amelia and suggests that p63 is essential for the initiation of this structure (Ianakiev et al. [@CR23]).

*TP63* mutations in humans are responsible for approximately 10-16 % of isolated SHFM cases (see Fig. [2d](#Fig2){ref-type="fig"}). On the other hand, mutations in this gene are found in 93 % of patients affected by EEC syndrome in which limb malformations occur as a part of the phenotypic spectrum (van Bokhoven et al. [@CR48]; de Mollerat et al. [@CR11]).

### SHFM5 (2q31) {#Sec8}

Deletions of chromosome 2q31 region encompassing the entire *HOXD* gene cluster (*HOXD1*-*HOXD13*) has been described in patients with SHFM, including monodactyly (Ramer et al. [@CR38]; Boles et al. [@CR7]; Del Campo et al. [@CR13]). However, Goodman et al. have suggested that a locus for SHFM5 is associated with the deletions in 2q31 region encompassing the 5-Mb interval centromeric to *EVX2* gene, which is located upstream of the *HOXD* cluster (Goodman et al. [@CR20]). The authors reported two families with limb malformations. In the first family, father and daughter were affected with synpolydactyly (SPD) caused by a deletion that involved 5' part of the *HOXD* gene cluster (*HOXD9*-*HOXD13*) and extended only 85 kb upstream of *HOXD13* encompassing *EVX2* gene. In the second family, the proband presented with bilateral split foot and deletion at 2q31-q33 comprising the entire *HOXD* cluster (*HOXD1*-*HOXD13*), *EVX2*, *DLX1* and *DLX2* up to microsatellite marker D2S294, located approximately 5 Mb centromeric to *EVX2* (Goodman et al. [@CR20]). On the 3' side of the cluster, the four remaining HOXD genes (*HOXD1*, *HOXD3*, *HOXD4*, *HOXD8*) are not expressed in the developing limbs (Goodman et al. [@CR20]). Taken together, these findings indicated that haploinsufficiency of 5' *HOXD* cluster causes SPD, but not SHFM, which is related to a locus located centromeric to *EVX2* on 2q31. Two genes *DLX1* and *DLX2*, that lie within this locus are putative candidate genes for ectrodactyly as both are expressed in the AER and PZ (Goodman et al. [@CR20]). However, neither heterozygous, nor homozygous *Dlx1*, *Dlx2*, and double *Dlx1*/*Dlx2* knock-out mice have limb malformations (Qiu et al. [@CR37]). Furthermore, no pathogenic mutations in those genes have been identified so far, thus their role in the pathogenesis of SHFM remains elusive.

### SHFM6 (12q13; *WNT10B*) {#Sec9}

To date only three consanguineous families and one sporadic case exhibiting autosomal recessive inheritance of SHFM have been reported (Ugur and Tolun [@CR47]; Blattner et al. [@CR6]; Khan et al. [@CR22]; Shamseldin et al. [@CR41]). As mentioned above, in one family SHFM was caused by a homozygous *DLX5* point mutation in SHFM1 locus (Shamseldin et al. [@CR41]). The three remaining cases of autosomal recessive SHFM resulted from homozygous mutations in *WNT10B*, a gene located within the SHFM6 locus. WNT proteins act as ligands in a variety of signaling pathways and play a major role in limb morphogenesis and development (Yang [@CR52]). Disease causing mutation in this gene was first described by Ugur and Tolun ([@CR47]), who identified a homozygous missense variant (p.R332W) in all affected members of the Turkish consanguineous family (with the exception of one mildly affected individual). Importantly, the homozygous mutation was also identified in one unaffected individual from the same family, which led to the assumption that the reported *WNT10B* variant is necessary, but not sufficient to produce SHFM. Therefore, the authors hypothesized the coexistence of a second locus that contributes to the phenotype or the presence of a suppressor mutation in the unaffected individual (Ugur and Tolun [@CR47]). Another description of an autosomal recessive SHFM concerned a Swiss patient with a homozygous 4-bp duplication in *WNT10B*. Interestingly, this was the sporadic case that gave a new insight to the genetic counseling of all patients with sporadic SHFM, as they were generally considered to have dominantly inherited *de novo* mutations (Blattner et al. [@CR6]). The recently reported novel homozygous mutation in *WNT10B* (p.T329R) was detected in a consanguineous Pakistani family with autosomal recessive SHFM in all of the affected family members (Khan et al. [@CR22]).

Other SHFM loci {#Sec10}
---------------

Split hand/foot malformation with long bone deficiency (SHFLD) involving tibia and fibula is most commonly associated with the duplication of 17p13.3 locus. The first report by Lezirovitz et al. ([@CR31]) of a large Brazilian family mapped the SHFLD to an 841 kb interval at 17p13.1-17p13.3 (Lezirovitz et al. [@CR31]). Next, Klopocki et al. ([@CR27]) found that the defect is caused by a tandem duplication and narrowed down the region to the smallest region of overlap, including only the single *BHLHA9* gene. The authors have investigated the expression pattern of *BHLHA9* mouse and zebrafish orthologs at different embryonic stages. The results of this study indicated that *Bhlha9* expression in both species was restricted to the AER of the limb bud mesenchyme. To further investigate the role of *BHLHA9* in limb development the authors have performed knockdown experiments in zebrafish embryos, which revealed that loss of protein function resulted in shortening of the pectoral fins, thus confirming its role in limb development (Klopocki et al. [@CR27]). Duplication in the 17p13.3 locus is responsible for approximately 12 % of SHFM without long bone involvement. One of the most interesting clinical aspects of this study was that SHFLD related to 17p13.3 locus showed a high degree of non-penetrance with sex bias, as approximately 50 % of the duplication carriers (particularly females) were unaffected. This may be due to the coexistence of another factor related to a hormone responsive element or modifier on the X-chromosome that together with 17p13.3 duplication led to the development of SHFLD (Klopocki et al. [@CR27]).

To date, there has been a single report describing a male patient who manifested SHFM probably due to a *de novo* 1 Mb deletion in chromosome 19p13.11. One gene included in this duplication - *EPS15L1* - was suggested by the authors as a candidate gene for SHFM (Aten et al. [@CR3]). EPS15L1 protein acts as a substrate for the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), which has been associated with limb development (Wong et al. [@CR51]). An indirect evidence for the role of *EPS15L1* in SHFM was provided by Bens et al. ([@CR4]) who described a patient with a *de novo* deletion partly overlapping with the copy number variant (CNV) detected by Aten et al. ([@CR3]). Interestingly, both patients shared most of the phenotypic features except from SHFM and also *EPS15L1* gene remained non-deleted in a patient without limb phenotype (Bens et al. [@CR4]). This genotype-phenotype correlation substantiates the hypothesis on *EPS15L1* as a potential candidate gene for SHFM, which nevertheless needs further support.

Frequent SHFM syndromes {#Sec11}
-----------------------

As mentioned above, ectrodactyly may occur either as an isolated malformation or coexists with other congenital anomalies such as cleft lip/palate, ectodermal dysplasia or developmental delay/mental retardation. There are several relatively frequent syndromes in which ectrodactyly occurs as one of the multiple congenital anomalies. The most common involve EEC syndrome (ectrodactyly-ectodermal dysplasia-cleft lip/palate syndrome), EEC syndrome without cleft lip/palate, LADD syndrome (lacrimo-auriculo-dento-digital syndrome), ADULT syndrome (acro-dermato-ungual-lacrimal-tooth syndrome), CHARGE syndrome or VATER association (see Table [1](#Tab1){ref-type="table"}).

Diagnostic aspects and genetic counseling {#Sec12}
-----------------------------------------

Diagnosis in a patient presenting with SHFM should be achieved on the basis of both careful clinical examination as well as relevant cytogenetic and/or molecular tests. Clinical features and the underlying genetic defects of SHFM have been described in detail in the above paragraph, hence we focus here on the diagnostic approach and genetic counseling.

As described above, at least seven SHFM types (i.e., six basic from SHFM1 to SHFM6 and one additional SHFM/SHFLD) have been distinguished in the literature (Blattner et al. [@CR6]; Klopocki et al. [@CR27]). The most common mode of inheritance for split hand/foot malformation is an autosomal dominant one with reduced penetrance (Duijf et al. [@CR15]), although autosomal recessive (Elliott et al. [@CR16]; Blattner et al. [@CR6]; Shamseldin et al. [@CR41]), as well as X-linked inheritance (Ahmad et al. [@CR2]) have also been reported. Sporadic cases with isolated SHFM most likely result from *de novo* mutations. In such a setting the recurrence risk for the proband's sib is very low, while for the proband's offspring is high and reaches 30-50 % (Blattner et al. [@CR6]). Considering reduced penetrance, variable expression or non-Mendelian inheritance as well as segregation distortion and sex bias (Klopocki et al. [@CR27]) with overtransmission of the genetic alteration from affected fathers to sons (Jarvik et al. [@CR25]), it becomes clear, that genetic counseling in SHFM cases is rather difficult and challenging, not only in sporadic but also in familial cases. Furthermore, many of the SHFM cases seem to originate from complex set of mutations/chromosomal aberrations and have to be regarded as two- or multigenic disorders. Consequently, if genetic counseling in SHFM is to be reliable and informative it should be based on the panel of relevant genetic testing. Importantly, for the significant proportion of the SHFM patients who are tested for all known causative alterations, genetic abnormalities remain uncovered. Hence, for those patients the exact recurrence risk is unknown and has to be predicted based on empirical data.

The first tier genetic test should account for the frequency of the underlying causative SHFM changes. The largest cohort of SHFM patients described to date comprised 56 cases (Klopocki et al. [@CR27]). The most frequent genetic abnormalities in this group were submicroscopic duplications of 10q24.3 (SHFM3) and 17p13.3 (SHFM/SHFLD) responsible for 20 % and 16 % of cases, respectively. Based on this finding and on our own diagnostic experience we propose that SHFM testing should begin with copy number screening for 10q24 followed by 17p13.3 loci. Array CGH (aCGH) would be the method of choice as it allows not only for the detection of these changes, but also for the identification of other unbalanced chromosomal aberrations such as submicroscopic rearrangements affecting different loci (i.e., SHFM1 or SHFM5). Since the vast majority of SHFM related aberrations involve around several hundred kbs of genomic DNA, the resolution of aCGH platforms does not have to be particularly high. Routine diagnostic arrays with the resolution of about 180 k oligonucleotide probes per haploid genome are sufficient for identifying most of the underlying CNVs. Alternatively, aCGH can be substituted by quantitative assays (such as MLPA or qPCR) for all known genomic SHFM loci. To our knowledge, there are no commercially available validated diagnostic MLPA or qPCR kits, therefore such tests have to be developed in-house and as a consequence they are less reliable. In some SHFM cases the conventional karyotyping is sufficient for diagnosis, as it can reveal a large chromosomal aberrations, such as deletions or translocations involving the 7q21-q22 region (Crackower et al. [@CR8]; Duijf et al. [@CR15]; Elliot and Evans [@CR17]), namely SHFM1 locus (Elliott et al. [@CR16]) or deletions of 2q31 (SHFM5) (Goodman et al. [@CR20]; Elliott et al. [@CR16]). Thus, basic GTG banding is still useful next to molecular testing, as it is a relatively cheap and informative assay in a subset of patients linked to SHFM1 or SHFM5 loci. An important advantage of karyotyping in reference to aCGH is its ability to detect balanced chromosomal rearrangements, for instance translocations, which are not infrequent in SHFM1 locus. Other patients presenting with isolated SHFM described so far (except for the tiny proportion of SHFM3) carry normal karyotypes. Conventional GTG banding should always be considered in syndromic SHFM especially in the case of association with additional congenital anomalies or mental retardation which are most common and severe in SHFM5 cases (Elliot and Evans [@CR17]). Another important diagnostic test in SHFM patients is the *TP63* gene sequencing. This is because point mutations in this gene give rise to about 10-16 % of isolated SHFM and may occur either *de novo* or have autosomal dominant inheritance with a 50 % recurrence risk. The *TP63* mutations show rather complete penetrance but highly variable expressivity (de Mollerat et al. [@CR11]).

The recently discovered SHFM6 locus contains the *WNT10B* gene (Ugur and Tolun [@CR47]). SHFM6-dependent defect is inherited in an autosomal recessive manner and is caused by either homozygous or compound heterozygous *WNT10B* mutations. Other autosomal recessive changes resulting in SHFM were very recently associated in a single family with homozygous *DLX5* mutations in the homeodomain of the gene (Shamseldin et al. [@CR41]). In the recessive inheritance model, the recurrence risk for proband\'s sib is 25 % whereas for proband\'s offspring is very low, unless there is consanguinity (Blattner et al. [@CR6]). Noteworthy, autosomal recessive SHFM seems to be exceptionally rare. So far it has been reported only in a few, usually consanguineous families. Therefore, sequencing of *WNT10* and *DLX5* genes should be considered at the end of the diagnostic algorithm (for summary and diagnostic flow-chart proposed by us, see Fig. [3](#Fig3){ref-type="fig"}, for a list of primers routinely used to sequence *TP63*, *WNT10B* and *DLX5* genes, see Table [2](#Tab2){ref-type="table"}).Fig. 3Diagnostic flow-chart useful in the planning of SHFM genetic diagnostics. Order of tests account for the relative frequencies of different SHFM causes as well as prices (in the case of karyotyping vs *TP63* sequencing). CNV -- copy number variation, AD -- autosomal dominant, AR -- autosomal recessive, WES -- whole exome sequencing, WGS -- whole genome sequencingTable 2Sequences of the primers used for *TP63*, *WNT10B* and *DLX5* genes amplification and sequencingExon nameF primer sequence 5'-3'R primer sequence 5'-3'TP63_e1TCCCGGCTTTATATCTATATATACGACACATTCATAATACACAAGGCACTP63_e2TCCACTTGGGTTTTCATGATAGAGGTAAGCAATATTTTGACCACCCACTP63_e3GCTTGTTGTTAACAACAGCATGGAAAAGACAGGTTTAACAGAGCTP63_e4GTGAAGTGCTTCCGACGTGTCCACCATGAACATGGAATCTP63_e5GTTGGTTCTCTCCTTCCTTTCGCCCACAGAATCTTGACCTTCTP63_e6CCACCAACATCCTGTTCATGCGTTCTCTCAAGTCTACTCAGTCCTP63_e7GGGAAGAACTGAGAAGGAACAACCAGCCACGATTTCACTTTGCCTP63_e8CAAGTGCTTTTGGGTCCATTCACTTGCTGCTGAAGGTCACTP63_e9ATGCATTAGTGCTTTAGAAGTGAAGGTTAAAATGAAGCAACCTP63_e10TGAGGATTGACCACACTTCTAACCATCAATCACCCTATTGCTGATCTP63_e11TGAACATCATTTCCATGTTTGTCTCACAGAGTCTTGTCCTAAGCTP63_e12GGACTATAACAGTATCCGCCCCAAGATGGACCACTGGGATGTP63_e13CTTATCTCGCCAATGCAGTTGGAACTACAAGGCGGTTGTCATCAGTP63_e14GGGAATGATAGGATGCTGTGGAAGATTAAGCAGGAGTGCTTDLX5_e1CTTAGACCAGAGCAGCCCCATCTACCACCCCATCTCGCDLX5_e2TCTATTTGAGGCCCTTCCGAGTCCCATCGAGACTGAACCDLX5_e3GTCCGAAGATGCCTCCAGTCCAGTTTTCCGAACTTCCCCWNT10B_e2GTGTCTGATTGGGCAAGGTTCTCATTGCTTAGAGCCCTGGWNT10B_e3GGAGAGTTGGAGGGGTCTGGAAACCATCCCTTCCCGCWNT10B_e4TGCCTGTCAACCTTACCTCCTAACCAGGCCTCAAAAGCTGWNT10B_e5TGTGCCTCTGTGTTCTGTCCGAAATCAGAGCAAAGGGCTG

Recent studies performed on a group of SHFLD cases and SHFM/SHFLD families have shown that duplications of 17p13.3 with the minimal region of overlap encompassing only the single *BHLHA9* gene are a frequent cause of isolated SHFM without deficiency of long bones (Klopocki et al. [@CR27]). Importantly, from the clinical point of view, the penetrance in this locus is reduced to about 50 % and the abnormality is often inherited from an unaffected parent. Of note, a strong sex bias has been observed with about 72 % of the affected individuals being males. On the other hand females are usually asymptomatic carriers, but once they are affected they usually present with a more severe phenotype. The authors estimated the risk for a healthy 17p13.3 duplication carrier to have an affected male or female offspring as 36 % and 15 %, respectively (Klopocki et al. [@CR27]).

Development and dissemination of the molecular diagnostic testing, including aCGH have allowed for substantial improvement of the diagnostic yield in various groups of patients, including SHFM or other congenital limb defects. Genetic and clinical heterogeneity of SHFM contributes to the exceptionally difficult and challenging genetic counseling, including the recurrence risk assessment. Therefore, identification of the genetic alteration responsible for SHFM in individual patients is of practical importance for the entire family. First, it helps the affected or at risk individuals to understand the nature of the genetic condition as well as the options in management and preventive or supportive measures that may be available. Secondly, it provides a solid foundation for the actual risk estimation allowing for a conscious family planning and for prenatal or pre-implantation diagnosis. Finally, by the exclusion of all known causative alterations, diagnostic testing creates an opportunity to qualify unresolved cases for research testing (i.e., whole exome or whole genome sequencing), thereby contributing to the discovery of novel causes of SHFM.
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